FDA clears troculeucel for expanded access program

FDA clears troculeucel for expanded access program

NKGen Biotech said it’s been cleared to launch an expanded access program (EAP) that will allow patients in the U.S. with neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS), to access its experimental therapy troculeucel outside clinical trials. EAPs, or compassionate use programs, allow people with serious or life-threatening conditions…

How I’m now dancing to the beat of my own ALS

I used to take for granted my ability to sync up with the people and events in my life — to keep up with conversations, move in unison with my fellow dancers, and show up on time. But that was before ALS waltzed into my life. At first, the…

Guest Voice: Dealing with ALS amid COVID-19 restrictions

Anita Newton is a retired science teacher who lives near Bristol, England. She taught chemistry for 30 years before retiring when her husband, Craig, was diagnosed with ALS. Her interests range from sports like pickleball, badminton, and table tennis to reading, writing, painting, and crafting. She also enjoys traveling…